{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:40:15Z","timestamp":1785858015447,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Bengbu Medical University Graduate Research Innovation Program","award":["Byycx24078"],"award-info":[{"award-number":["Byycx24078"]}]},{"name":"This study was supported by Natural Science Research Project of Bengbu Medical University","award":["2023byzd086"],"award-info":[{"award-number":["2023byzd086"]}]},{"name":"Anhui Provincial College Student Innovation and Entrepreneurship Training Program","award":["S202410367145"],"award-info":[{"award-number":["S202410367145"]}]},{"name":"Health Research Program of Anhui","award":["AHWJ2023A10059"],"award-info":[{"award-number":["AHWJ2023A10059"]}]},{"name":"outstanding young backbone talents in colleges and universities abroad visiting study and training project","award":["gxgwfx2021030"],"award-info":[{"award-number":["gxgwfx2021030"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02841-4","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T15:24:40Z","timestamp":1749482680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrated bioinformatics and functional studies identify CDK9 as a potential prognostic biomarker and therapeutic target in AML"],"prefix":"10.1007","volume":"16","author":[{"given":"Zhibin","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"2841_CR1","doi-asserted-by":"crossref","unstructured":"Pollyea DA, Altman JK, Assi R, et al. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.\u00a0J Natl Compr Canc Netw. 2023;21(5):503\u201313.","DOI":"10.6004\/jnccn.2023.0025"},{"issue":"23","key":"2841_CR2","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"2841_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","volume":"14","author":"H Liu","year":"2021","unstructured":"Liu H. Emerging agents and regimens for AML. J Hematol Oncol. 2021;14(1):49.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2841_CR4","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/cncr.33458","volume":"127","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, Ravandi F, Kadia TM, et al. De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021;127(12):2049\u201361.","journal-title":"Cancer"},{"issue":"5","key":"2841_CR5","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.cell.2018.09.051","volume":"175","author":"H Zhang","year":"2018","unstructured":"Zhang H, Pandey S, Travers M, et al. Targeting CDK9 reactivates epigenetically silenced genes in cancer. Cell. 2018;175(5):1244-1258.e26.","journal-title":"Cell"},{"issue":"3","key":"2841_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2159-8290.CD-19-0528","volume":"10","author":"J Chou","year":"2020","unstructured":"Chou J, Quigley DA, Robinson TM, et al. Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy. Cancer Discov. 2020;10(3):351\u201370.","journal-title":"Cancer Discov"},{"issue":"4","key":"2841_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3390\/ph16040519","volume":"16","author":"M Klein","year":"2023","unstructured":"Klein M. Targeting protein-protein interactions to inhibit cyclin-dependent kinases. Pharmaceuticals (Basel). 2023;16(4):519.","journal-title":"Pharmaceuticals (Basel)"},{"key":"2841_CR8","doi-asserted-by":"crossref","unstructured":"Nilmani, D'costa M, Bothe A, et al. CDK regulators-cell cycle progression or apoptosis-scenarios in normal cells and cancerous cells. Adv Protein Chem Struct Biol. 2023;135:125\u201377.","DOI":"10.1016\/bs.apcsb.2022.11.008"},{"issue":"3","key":"2841_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s13258-022-01351-9","volume":"45","author":"M Park","year":"2023","unstructured":"Park M, Cho JH, Moon B, et al. CDK9 inhibitors downregulate DKK1 expression to suppress the metastatic potential of HCC cells. Genes Genomics. 2023;45(3):285\u201393.","journal-title":"Genes Genomics"},{"issue":"10","key":"2841_CR10","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1002\/1878-0261.12559","volume":"13","author":"MH Rahaman","year":"2019","unstructured":"Rahaman MH, Lam F, Zhong L, et al. Targeting CDK9 for treatment of colorectal cancer. Mol Oncol. 2019;13(10):2178\u201393.","journal-title":"Mol Oncol"},{"issue":"3","key":"2841_CR11","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41416-020-01135-6","volume":"124","author":"L Yang","year":"2021","unstructured":"Yang L, Zhou F, Zhuang Y, et al. Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9\/STAT3 signalling pathway. Br J Cancer. 2021;124(3):645\u201357.","journal-title":"Br J Cancer"},{"issue":"9","key":"2841_CR12","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.3390\/cancers13092181","volume":"13","author":"R Mandal","year":"2021","unstructured":"Mandal R, Becker S, Strebhardt K. Targeting CDK9 for anti-cancer therapeutics. Cancers (Basel). 2021;13(9):2181.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2841_CR13","doi-asserted-by":"publisher","first-page":"2219470","DOI":"10.1080\/15384047.2023.2219470","volume":"24","author":"L Xiao","year":"2023","unstructured":"Xiao L, Liu Y, Chen H, et al. Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments. Cancer Biol Ther. 2023;24(1):2219470.","journal-title":"Cancer Biol Ther"},{"key":"2841_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116470","volume":"229","author":"C Mo","year":"2024","unstructured":"Mo C, Wei N, Li T, et al. CDK9 inhibitors for the treatment of solid tumors. Biochem Pharmacol. 2024;229: 116470.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2841_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13046-018-0704-8","volume":"37","author":"S Boffo","year":"2018","unstructured":"Boffo S, Damato A, Alfano L, et al. CDK9 inhibitors in acute myeloid leukemia. J Exp Clin Cancer Res. 2018;37(1):36.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"2841_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124673","volume":"10","author":"HX Jin","year":"2015","unstructured":"Jin HX, Go ML, Yin P, et al. Determining the functions of HIV-1 Tat and a second magnesium ion in the CDK9\/Cyclin T1 complex: a molecular dynamics simulation study. PLoS ONE. 2015;10(4): e0124673.","journal-title":"PLoS ONE"},{"issue":"5","key":"2841_CR17","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/ijc.26127","volume":"130","author":"X Liu","year":"2012","unstructured":"Liu X, Shi S, Lam F, et al. CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol. Int J Cancer. 2012;130(5):1216\u201326.","journal-title":"Int J Cancer"},{"issue":"1A","key":"2841_CR18","first-page":"A68","volume":"19","author":"K Tomczak","year":"2015","unstructured":"Tomczak K, Czerwi\u0144ska P, Wiznerowicz M. The cancer genome atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68\u201377.","journal-title":"Contemp Oncol (Pozn)"},{"key":"2841_CR19","doi-asserted-by":"crossref","unstructured":"Goldman M, Craft B, Swatloski T, et al. The UCSC cancer genomics browser: update 2015.\u00a0Nucleic Acids Res. 2015;43(Database issue):D812\u20137.","DOI":"10.1093\/nar\/gku1073"},{"key":"2841_CR20","doi-asserted-by":"crossref","unstructured":"Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells.\u00a0Nucleic Acids Res. 2020;48(W1):W509\u2013W514.","DOI":"10.1093\/nar\/gkaa407"},{"issue":"D1","key":"2841_CR21","doi-asserted-by":"publisher","first-page":"D956","DOI":"10.1093\/nar\/gkx1090","volume":"46","author":"SV Vasaikar","year":"2018","unstructured":"Vasaikar SV, Straub P, Wang J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956\u201363.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2841_CR22","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.","journal-title":"Nat Commun"},{"issue":"D1","key":"2841_CR23","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638\u201346.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"2841_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11912-024-01503-y","volume":"26","author":"M Wysota","year":"2024","unstructured":"Wysota M, Konopleva M, Mitchell S. Novel therapeutic targets in acute myeloid leukemia (AML). Curr Oncol Rep. 2024;26(4):409\u201320.","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"2841_CR25","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamaoncol.2024.2662","volume":"10","author":"S Venugopal","year":"2024","unstructured":"Venugopal S, Sekeres MA. Contemporary management of acute myeloid leukemia: a review. JAMA Oncol. 2024;10(10):1417\u201325.","journal-title":"JAMA Oncol"},{"issue":"1","key":"2841_CR26","doi-asserted-by":"publisher","first-page":"2450859","DOI":"10.1080\/15384047.2025.2450859","volume":"26","author":"Q Zhu","year":"2025","unstructured":"Zhu Q, Cheng J, Gao Y, et al. NVP-2, in combination with Orlistat, represents a promising therapeutic strategy for acute myeloid leukemia. Cancer Biol Ther. 2025;26(1):2450859.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"2841_CR27","first-page":"3115","volume":"18","author":"J Organista-Nava","year":"2019","unstructured":"Organista-Nava J, G\u00f3mez-G\u00f3mez Y, Del Moral-Hernandez O, et al. Deregulation of folate pathway gene expression correlates with poor prognosis in acute leukemia. Oncol Lett. 2019;18(3):3115\u201327.","journal-title":"Oncol Lett"},{"key":"2841_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.811144","volume":"13","author":"T Menter","year":"2022","unstructured":"Menter T, Tzankov A. Tumor microenvironment in acute myeloid leukemia: adjusting niches. Front Immunol. 2022;13: 811144.","journal-title":"Front Immunol"},{"key":"2841_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116132","volume":"171","author":"Y Wu","year":"2024","unstructured":"Wu Y, Li Y, Gao Y, et al. Immunotherapies of acute myeloid leukemia: rationale, clinical evidence and perspective. Biomed Pharmacother. 2024;171: 116132.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2841_CR30","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","volume":"9","author":"S Chen","year":"2024","unstructured":"Chen S, Zhu H, Jounaidi Y. Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Signal Transduct Target Ther. 2024;9(1):302.","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"2841_CR31","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.3390\/cancers16162915","volume":"16","author":"H Salman","year":"2024","unstructured":"Salman H. Comparative analysis of AML classification systems: evaluating the WHO, ICC, and ELN frameworks and their distinctions. Cancers (Basel). 2024;16(16):2915.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2841_CR32","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3324\/haematol.2022.281443","volume":"108","author":"H Pariury","year":"2023","unstructured":"Pariury H, Fandel J, Bachl S, et al. Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia. Haematologica. 2023;108(5):1272\u201383.","journal-title":"Haematologica"},{"key":"2841_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116568","volume":"471","author":"JC Lin","year":"2023","unstructured":"Lin JC, Liu TP, Chen YB, et al. Inhibition of CDK9 exhibits anticancer activity in hepatocellular carcinoma cells via targeting ribonucleotide reductase. Toxicol Appl Pharmacol. 2023;471: 116568.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"2841_CR34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12885-023-10540-y","volume":"23","author":"T Sakamoto","year":"2023","unstructured":"Sakamoto T, Ajiro M, Watanabe A, et al. Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy. BMC Cancer. 2023;23(1):71.","journal-title":"BMC Cancer"},{"key":"2841_CR35","doi-asserted-by":"publisher","first-page":"204062072093376","DOI":"10.1177\/2040620720933761","volume":"11","author":"P Johansson","year":"2020","unstructured":"Johansson P, Dierichs L, Klein-Hitpass L, et al. Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemia. Ther Adv Hematol. 2020;11:2040620720933761.","journal-title":"Ther Adv Hematol"},{"issue":"10","key":"2841_CR36","doi-asserted-by":"publisher","first-page":"5476","DOI":"10.3390\/ijms23105476","volume":"23","author":"MDM Noblejas-L\u00f3pez","year":"2022","unstructured":"Noblejas-L\u00f3pez MDM, Gandullo-S\u00e1nchez L, Gal\u00e1n-Moya EM, et al. Antitumoral activity of a CDK9 PROTAC compound in HER2-positive breast cancer. Int J Mol Sci. 2022;23(10):5476.","journal-title":"Int J Mol Sci"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02841-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02841-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02841-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T15:24:42Z","timestamp":1749482682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02841-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2841"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02841-4","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"29 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the Institutional Review Committee of the First Affiliated Hospital of Bengbu Medical University, The registration number is [2024] KY019. This study was conducted in accordance with the declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1038"}}